A Phase 2 interventional study of Bivalent RSV+HMPV protein vaccine and Placebo in Respiratory Syncytial Virus, Human Metapneumovirus and Healthy Volunteers, sponsored by Sanofi. Recruiting at 21 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Sanofi · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy, safety, and immunogenicity of a single IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate.
The study will include a Safety Lead-in Cohort that will be enrolled first and will comprise 200 participants aged 60 years and older randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo (100 participants per arm).
The enrollment of the Main Cohort will start after the completion of the ESDR (Early Safety Data Review), pending a positive outcome. For the Main Cohort, 7800 participants (3900 participants per arm) will be randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate
Biological: Bivalent RSV+HMPV protein vaccine
Single administration of matching placebo
Biological: Placebo
Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate
Biological: Bivalent RSV+HMPV protein vaccine
Single administration of matching placebo
Biological: Placebo
IM injection
Also known as: RPF08203
IM injection
Occurrence of the first episode of RSV-LRTD (Lower Respiratory Tract Disease)
Time frame: From 14 days to 12 months after vaccination
Occurrence of the first episode of HMPV-LRTD
Time frame: From 14 days to 12 months after vaccination
Occurrence of the first episode of RSV-LRTD and/or HMPV-LRTD
Time frame: From 14 days to 12 months after vaccination
Occurrence of the first episode of RSV-ARD (Acute Respiratory Disease) and/or HMPV-ARD
Time frame: From 14 days to 12 months after vaccination
Occurrence of the first episode of severe RSV-LRTD and/or severe HMPV-LRTD
Time frame: From 14 days to 12 months after vaccination
Occurrence of the first episode of RSV-URTD and/or HMPV-URTD
Time frame: From 14 days to 12 months after vaccination
RSV A, RSV B, and HMPV A, HMPV B serum nAb titers in a subset of participants
Time frame: At pre-vaccination and 8 days, 28 days, 6 months and 12 months post- vaccination
Presence of immediate unsolicited systemic AEs (Adverse Events)
Time frame: Within 30 minutes after vaccination
Presence of solicited injection site and systemic reactions in a subset of participants
Time frame: Up to 7 days after vaccination
Presence of unsolicited AEs reported
Time frame: Up to 27 days after vaccination
Presence of MAAEs (Medically Attended Adverse Events)
Time frame: Within 6 months after vaccination
Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Event of Special Interest)
Time frame: Within 6 months after vaccination
Presence of related SAEs, related AESIs, and fatal SAEs
Time frame: Up to 12 months post-vaccination
Presence of out-of-range biological test results in a subset of participants
Time frame: 7 days after vaccination
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.